IN PARTNERSHIP
https://blog.navitus.com/specialty- pipeline-2021 Cancer is a disease that is frequently treated
O
over the long term, and even when the cancer has been eliminated, follow-up continues for years. As a result, the end points to assess efficacy tend to look at the effect over time and its endurance, not just a static assessment of whether the disease is cured, as in many other therapeutic areas. The challenges associated with this in the context of submission dossiers arise from the fact that there are often multiple interim study reports, in addition to the final CSR (clinical study report), and multiple data cuts over time (sometimes with different data cuts across multiple studies, which can be tricky to explain to the reader of a submission). Cancer therapy is also a dynamic area, with developments in biotechnology rapidly shifting the approach to treatment. The medical dogma in many cancer types can shift swiftly, which means that the scientific rationale, available treatments, and medical need descriptions must often be updated frequently – sometimes changing considerably, even within a 12-month period, as new treatment options alter the therapeutic landscape. The role of the medical writer in the dossier- writing process is to collaborate with the clinical experts to understand their vision for the treatment being studied and to crystallise the messaging from the clinical programme. The medical writers need to come to terms with the oncology-specific terminology, acronyms and efficacy endpoints (progression-free survival, overall response rate, duration of response). They
6 |
also need to work with the clinical teams to know where current changes in the medical opinion might need to be reflected in the medical need discussion and to understand how the product under assessment needs to be positioned in the overall picture of available therapies. Frequently, because the clinical experts are often deeply involved in the research going on in their area, the medical writers need to help the experts step back from the minutiae and look at the big picture in the context of a registration dossier. It is important that the regulatory documents stay focused on what is needed to get regulatory approval of the target product profile (TPP) and not get off target and bogged down by academic questions (that can be interesting but should be saved for publications). To do this effectively, it is essential that submission teams have a clear and well developed TPP from the start of a clinical development programme. Ideally, the programme should be reverse engineered to specifically collect the data that will be needed to support the intended claims of the TPP. At the latest, it should be ready by the time writing on a submission dossier begins. Without the TPP, it can be challenging to know what aspects to focus on in the Module 2 summaries. If written in parallel, it often gets in the way of writing the dossier as the team chases a moving target. Having the TPP ready and agreed on well in advance gives the team clarity on what issues to focus on throughout the clinical programme, in general, and when writing the CTD (common technical document) summaries, in particular. During an oncology clinical programme, it is not uncommon to have multiple dose modifications as the investigators adapt to manage AEs and slowly home in on the optimal dose regimen. Early studies can have different dosing regimens than later studies. As a result,
“It is important that the regulatory documents stay focused on what is needed to get regulatory approval of the target product profile, and not get off target and bogged down by academic questions”
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50
